Synthesis of 3-ethoxycarbonyl-4-hydroxy-1,4-dihydroazolo[5,1- <i>c</i> ][1,2,4]triazines and study of antiglycation activity

A novel method for the synthesis of a series of 3-ethoxycarbonyl-4-hydroxy-1,4-dihydroazolo[5,1-c][1,2,4]triazine derivatives was developed using ethyl-3-morpholinoacrylate as a key azo component. The synthesized compounds were evaluated for their antiglycation activity. It was found that the obtained compounds demonstrated significantly higher efficacy compared to aminoguanidine as a well-known reference drug. Among the derivatives, compound 9g exhibited the most potent activity, surpassing aminoguanidine by 2.1 times with IC50 values of 999.0 µM and 2134.5 µM, respectively. The use of the MTT assay allowed investigating the cytotoxicity of the lead compound, which showed the absence of cytotoxic properties and the presence of a cytovitalizing effect at a concentration of 10 μM, indicating its potential as a promising candidate for the development of new antidiabetic agents. These findings highlight the potential of azolotriazine derivatives as a foundation for further pharmacological exploration and drug design in the treatment of diabetes and its complications.